Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive cocktail targets Hard-to-Treat breast cancer

NCT ID NCT05870579

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new combination of drugs for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. The experimental treatment includes a radioactive drug (lutetium NeoB) that targets cancer cells, plus two standard hormone therapies (ribociclib and fulvestrant). The main goal is to find a safe dose and check for side effects in about 22 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lutetium NeoB (a radioactive drug) combined with ribociclib and fulvestrant
What this could lead to
If successful, this could provide a new treatment option for people with advanced breast cancer that no longer responds to standard hormone therapy.
What could go wrong
This is a very early, small phase 1 trial focused on safety and dosing, so it is not yet known if the combination is effective. There are also risks of side effects from the radioactive drug and the other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Novartis Investigative Site

    Shanghai, 200032, China

  • Novartis Investigative Site

    Saint-Cloud, Hauts De Seine, 92210, France

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Saint-Herblain, 44805, France

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Gliwice, 44 101, Poland

  • Novartis Investigative Site

    Porto, 4200-072, Portugal

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • UCLA Jonsson Comp Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.